We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Machines Designed to Deliver Drugs to Diseased Cells

By LabMedica International staff writers
Posted on 09 Sep 2010
A newly developed nanomaterial could improve therapeutics and imaging in cancer treatment.

Korean and U.S. More...
scientists from the University of California, Los Angeles (UCLA) California NanoSystems Institute (USA) and Yonsei University (Seoul, Korea) have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field. The new system--the first to utilize a class of porous nanomaterials driven by a magnetic core--has the potential to improve both targeted drug-delivery and magnetic resonance imaging (MRI) in the treatment of cancer and other diseases.

The research was published in the July 2010 issue of the Journal of the American Chemical Society. In recent years, cancer research has increasingly focused on developing therapies that, unlike chemotherapy, target only cancer cells while leaving healthy cells unharmed. To that end, scientists have created nanomachines that can trap and release drug molecules from pores directly into individual cancer cells in response to a stimulus.

While many methods have been created for controlling how and when pores load and unload their cargos, for therapeutic applications, an external and noninvasive method of activation is preferable for the most effective results.

The new method, developed by the research groups of Dr. Jeffrey Zink, a UCLA professor of chemistry and biochemistry, and Dr. Jinwoo Cheon, a professor of chemistry at Yonsei University, utilized a material that combines a framework of mesoporous silica nanoparticles with magnetic zinc-doped iron oxide nanocrystals, along with attached nanovalves that help hold drug molecules in the pores. When a magnetic-field stimulus is applied, the valves open and release the drug molecules from the pores into the target cells.

"The hydrophobic nature of the interior of the pores, as well as the ability to functionalize the silica surface with hydrophilic functionalities, makes these particles attractive for anti-cancer drug delivery," Dr. Zink noted. "Adding a magnetic core to the silica-based nanoparticles is of interest for its potential applications in magnetic resonance imaging, as addition of the magnetic core may make it useful as a contrast agent."

For this study, nanoparticles carrying the anticancer drug doxorubicin were introduced to and endocytosed by breast cancer cells. When the cancer cells containing the nanoparticles were then exposed to an oscillating magnetic field, cell death occurred. "The novel magnetic-core silica nanoparticles are effective in activating nanovalves which release anticancer drugs when they are exposed to an oscillating magnetic field," Dr. Zink said.

The magnetic-field oscillation causes the zinc-doped iron oxide nanocrystals to heat. This increased heat causes the molecular machines to activate, and the doxorubicin in the pores is delivered into the cells. "Magnetic nanocrystals are important in biomedical applications because they can be used for both therapeutics and imaging," said Dr. Cheon, director of the National Creative Research Initiative Center for Evolutionary Nanoparticles and a professor of chemistry and division head of the Nano-Medical National Core Research Center at Yonsei University. "The ability to deliver anticancer drugs only to the cancer cells without affecting healthy cells is of key importance," added Dr. Cheon who is also a visiting professor at UCLA's CNSI.

The next step in the research will be to evaluate the effects in vivo and to determine if it can be used to offer precise control over location of delivered drugs. The ultimate AIM would be to develop this system to have applicability in treatment of cancer patients.

Related Links:
University of California, Los Angeles' California NanoSystems Institute
Yonsei University




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.